조직은행 시장 보고서 : 제품별, 용도별, 조직 유형별, 지역별(2026-2034년)

The global tissue banking market size reached USD 2.2 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 5.0 Billion by 2034, exhibiting a growth rate (CAGR) of 9.20% during 2026-2034. The burgeoning research and development (R&D) investments, advancements in cryopreservation, the rise in chronic diseases and genetic disorders, growing demand for personalized medicine, improvements in genomics, regulatory advancements, strategic collaborations, and enhanced awareness among researchers are some of the factors boosting the market growth.

TISSUE BANKING MARKET ANALYSIS :

• Major Market Drivers: The global market for tissue banking is driven by the expediating progress in regenerative medicine and growing adoption of organ transplantation procedures. Increasing number of initiatives undertaken by the government and rising awareness regarding tissue donation are other factors expected to drive the market growth. Moreover, surging focus on the development of tissue preservation and storage techniques that are more viable and offer longer shelf life is another growth-inducing factor for the market. With the increasing rate of chronic diseases and trauma cases, the demand for tissue banking is growing exponentially, which is another factor stimulating the market growth. Apart from this, expanding healthcare infrastructure especially in developing countries is facilitating the market growth. Other factors, such as mounting investments into biobanking and personalized medicine and escalating collaborations among research institutions and tissue banks, are promoting the market growth.
• Key Market Trends: The development of automated tissue processing and preservation systems, which has helped minimize the amount of time taken to do a process with reduced human error, is one of the primary market trends. The escalating use of artificial intelligence (AI) and machine learning (ML) in tissue banking to improve data management is creating a positive outlook for the market growth. In line with this, stringent ethical regulations has compelled the tissue baking players to standardize their operations, which is further fueling the market growth. Moreover, the escalating collaboration between biopharmaceutical companies and tissue banks and surging attention on the cryopreservation methods are propelling the market growth.
• Geographical Trends: North America holds a leading share in the global tissue banking market as it is backed by a strong healthcare infrastructure, higher awareness about tissue donation, and significant investments in medical research. The region's dominance is also due to the strong presence of key market players and advanced technological capabilities. Europe's market growth is propelled by favorable governmental contexts and robust public health systems. Asia-Pacific's tissue banking market is bolstered by the burgeoning healthcare expenditure, expanding biobanking initiatives, and growing number of tissue transplantation.
• Competitive Landscape: Some of the major market players in the tissue banking industry include AMS Biotechnology, Beckman Coulter Inc. (Danaher Corporation), Bio-Rad Laboratories Inc., Brooks Life Sciences Inc. (Brooks Automation Inc.), Eppendorf AG, Merck KGaA, PHC Corporation, QIAGEN N.V., Sartorius AG, Taylor-Wharton, Thermo Fisher Scientific Inc., VWR International LLC (Avantor Inc), among many others.
• Challenges and Opportunities: The factors creating challenges for the market include stringent regulatory requirements, ethical issues about tissue donation and processing, and the high costs of sophisticated storage methods. The quality and safety of stored tissues is aptly the primary concern, which entails adherence to stringent standards. Tissue donation rates are limited in some parts due to low level of awareness and cultural barriers. However, they also offer various opportunities for market development, such as the increasing tissue donation rates due to burgeoning public awareness and education. Affordability is another factor that preservation technology and storage solution providers can consider to address.

TISSUE BANKING MARKET TRENDS:

Increasing Investments in Research and Development

The global tissue banking market is predominantly driven in growth by the increasing investment in R&D, especially for regenerative medicine and personalized therapies. With the advancements in disease understanding and treatment by scientific and medical communities, there is a significant growth in tissue sample donations, which is further fueling the market growth. These samples are key to understanding the biology of disease, testing new drugs for potential use in patients, and identifying patient populations that may benefit from a particular drug. As research progresses in fields such as stem cell therapy and gene editing, it thrusts the reliance on specific tissue samples, further increasing the demand for well-preserved banks of tissues accessible by everyone. For instance, recently, UC San Francisco launched the world's first tissue bank with samples donated by patients with long COVID. The move follows research indicating that the virus can continue to linger throughout the body and may hold the key to understanding the cause of the debilitating disorder and lead to effective treatments.

Advances in Cryopreservation Technologies

The development of cryopreservation technologies is one of the major factors which is pushing the global tissue banking market. Cryopreservation is an effective way to store living tissue and cells below freezing temperatures while keeping it viable. Rapidly advancing technologies have accelerated this process, making the quality of preserved tissues and their durability much better. Additionally, new cryoprotectants and cooling techniques are developed, such as vitrification that prevents ice crystal formation, which can otherwise damage cell structures. Moreover, automation in cryopreservation further automates the operations and helps in minimizing human error and increasing throughput, which is bolstering the market growth.

Growing Prevalence of Chronic Diseases and Genetic Disorders

The growing incidence of genetic diseases and chronic conditions is one of the primary factor accelerating the global tissue banking market. As per the national survey carried out in Saudi population, Diabetes Mellitus (DM) among adult males and females were estimated with prevalence rates 14.8% for male, while it was lower for female group where 11.7%. Chronic conditions such as cancer, cardiovascular diseases, and diabetes require extensive research to understand their pathophysiology and develop effective treatments. Tissue banks provide critical resources for this research by offering a diverse array of biological samples, which are essential for studying disease mechanisms, developing new drugs, and testing treatment efficacy.

TISSUE BANKING MARKET SEGMENTATION:

Breakup by Product:

• Equipment
  • Cryopreservation Equipment
  • Thawing Equipment
  • Quality Control Equipment
  • Others
• Media and Consumables

Equipment accounts for the majority of the market share

The equipment segment is driven by the increasing demand for advanced and reliable systems for tissue preservation and analysis. Technological advancements, such as automation and improved cryopreservation techniques, are crucial in enhancing the efficiency and accuracy of tissue handling and storage. The rise in research activities and clinical trials necessitates state-of-the-art equipment to ensure high-quality and reproducible results. Additionally, the growing focus on personalized medicine and regenerative therapies fuels the need for specialized equipment capable of managing diverse and complex tissue samples. Regulatory requirements for quality and safety standards further drive the adoption of sophisticated equipment. Increased investments in healthcare infrastructure and the expansion of tissue banks globally also contribute to the demand for advanced equipment.

Breakup by Application:

• Therapeutics
• Medical Research

Therapeutics holds the largest share of the industry

The therapeutics segment is driven by the increasing demand for personalized medicine, which necessitates the use of specific, high-quality tissue samples to tailor treatments to individual genetic profiles. Advances in genomics and biotechnology further fuel this growth, as they enable researchers and clinicians to better understand complex disease mechanisms and develop targeted therapies. Additionally, the rising prevalence of chronic diseases and genetic disorders accelerates the need for innovative therapeutic solutions, leading to a surge in research and development activities. Technological advancements in drug discovery, including high-throughput screening and sophisticated bioinformatics tools, are also pivotal, as they rely on diverse and well-characterized biological samples to identify and validate new therapeutic targets. The growing emphasis on regenerative medicine and cell therapies, such as stem cell treatments and tissue engineering, drives demand for robust tissue banking infrastructure, which provides essential materials for these cutting-edge therapies.

Breakup by Tissue Type:

• Cardiovascular Tissue
• Lung Tissue
• Kidney Tissue
• Pancreas Tissue
• Liver Tissue
• Eye Tissue

Cardiovascular Tissue represents the leading market segment

The cardiovascular tissue segment is driven by the increasing prevalence of cardiovascular diseases (CVDs), which are among the leading causes of mortality globally. This surge in CVD cases necessitates extensive research and development efforts, fueling the demand for high-quality cardiovascular tissues for studying disease mechanisms, developing innovative treatments, and testing therapeutic interventions. Advances in tissue engineering and regenerative medicine are also pivotal, as they enable the creation and use of cardiovascular tissues for developing personalized therapies and improving patient outcomes. The growing emphasis on personalized medicine further drives demand, as clinicians seek tissue samples that match individual patient profiles for more effective treatment plans. Additionally, ongoing advancements in biobanking technologies, including improved preservation methods and better tissue characterization techniques, enhance the quality and availability of cardiovascular tissues.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America leads the market, accounting for the largest tissue banking market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for tissue banking.

The North America regional market is driven by the increasing investments in healthcare research and biotechnology, which significantly bolster the demand for high-quality tissue samples. The presence of advanced research institutions and a robust pharmaceutical industry in the region accelerates the need for well-maintained tissue banks to support innovative studies in regenerative medicine, personalized therapies, and drug development. Additionally, the growing prevalence of chronic diseases and genetic disorders in North America drives the need for diverse tissue samples to understand disease mechanisms and develop effective treatments. Technological advancements in cryopreservation and tissue storage further enhance the market, providing solutions that extend the viability of preserved tissues and improve overall research quality. The regulatory landscape in North America also plays a crucial role; stringent standards and guidelines ensure the quality and safety of tissue banking practices, which in turn fosters trust and reliability in tissue banks.

COMPETITIVE LANDSCAPE:

• The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the tissue banking industry include AMS Biotechnology, Beckman Coulter Inc. (Danaher Corporation), Bio-Rad Laboratories Inc., Brooks Life Sciences Inc. (Brooks Automation Inc.), Eppendorf AG, Merck KGaA, PHC Corporation, QIAGEN N.V., Sartorius AG, Taylor-Wharton, Thermo Fisher Scientific Inc., VWR International LLC (Avantor Inc), etc. ()
• Key players in the tissue banking market are actively engaged in a variety of strategic initiatives to enhance their market position and drive innovation. Leading companies are investing heavily in R&D to advance cryopreservation technologies, improve tissue storage methods, and develop new applications for tissue samples. This includes implementing cutting-edge automation and digital solutions to streamline operations, increase efficiency, and ensure high-quality preservation of biological materials. Additionally, these players are expanding their global footprint by establishing new tissue banks and forming strategic partnerships with academic institutions, biopharmaceutical companies, and healthcare organizations. To address the growing demand for specialized and well-characterized tissue specimens, key players are also focusing on diversifying their tissue collections and incorporating advanced genomic and molecular characterization techniques. Moreover, regulatory compliance and the establishment of rigorous quality control standards are priorities, ensuring that their practices meet international guidelines and enhance the reliability of tissue resources.

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Tissue Banking Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Equipment
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Cryopreservation Equipment
    • 6.1.2.2 Thawing Equipment
    • 6.1.2.3 Quality Control Equipment
    • 6.1.2.4 Others
  • 6.1.3 Market Forecast
• 6.2 Media and Consumables
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Application

• 7.1 Therapeutics
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Medical Research
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Others
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Tissue Type

• 8.1 Cardiovascular Tissue
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Lung Tissue
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Kidney Tissue
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Pancreas Tissue
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Liver Tissue
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast
• 8.6 Eye Tissue
  • 8.6.1 Market Trends
  • 8.6.2 Market Forecast
• 8.7 Others
  • 8.7.1 Market Trends
  • 8.7.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 AMS Biotechnology
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
  • 14.3.2 Beckman Coulter Inc. (Danaher Corporation)
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 SWOT Analysis
  • 14.3.3 Bio-Rad Laboratories Inc.
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Brooks Life Sciences Inc. (Brooks Automation Inc.)
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
  • 14.3.5 Eppendorf AG
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 SWOT Analysis
  • 14.3.6 Merck KGaA
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 PHC Corporation
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
  • 14.3.8 QIAGEN N.V.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Sartorius AG
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Taylor-Wharton
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
  • 14.3.11 Thermo Fisher Scientific Inc.
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials
    • 14.3.11.4 SWOT Analysis
  • 14.3.12 VWR International LLC (Avantor Inc)
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio